Edith T Zemanick
Overview
Explore the profile of Edith T Zemanick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zuckerman J, Hinton A, Lahiri T, Teneback C, Jia S, Mermis J, et al.
Pediatr Pulmonol
. 2025 Jan;
60(1):e27487.
PMID: 39835779
Objective: Although studies have examined changes in C-reactive protein (CRP) during pulmonary exacerbations (PEX) in people with cystic fibrosis (PwCF), few have evaluated CRP profiles across age groups. Here, we...
2.
Liu C, Fischer J, Zemanick E, Woods J, Markarian K, Fain S, et al.
ERJ Open Res
. 2025 Jan;
11(1.
PMID: 39811548
Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are prevalent disease complications in people with cystic fibrosis. These understudied comorbidities significantly impact quality of life. The impact of highly effective...
3.
Zemanick E, Ramsey B, Sands D, McKone E, Fajac I, Taylor-Cousar J, et al.
J Cyst Fibros
. 2025 Jan;
PMID: 39755444
Background: Highly effective CFTR modulators improve CFTR function and lead to dramatic improvements in health outcomes in many people with cystic fibrosis (pwCF). The relationship between measures of CFTR function,...
4.
Metcalf A, Martiniano S, Sagel S, Zaretsky M, Zemanick E, Hoppe J
J Cyst Fibros
. 2024 Dec;
PMID: 39645477
As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including elexacaftor/tezacaftor/ivacaftor (ETI) have become widely used in eligible patients with cystic fibrosis (CF), the use of these medications in pregnant...
5.
Zemanick E, Rosas-Salazar C
Clin Chest Med
. 2024 Jul;
45(3):587-597.
PMID: 39069323
Numerous studies have examined the role of the microbiome and microbiome-based therapeutics in many childhood airway and lung diseases. In this narrative review, the authors first give a brief overview...
6.
Hoppe J, Sjoberg J, Hong G, Poch K, Zemanick E, Thee S, et al.
J Cyst Fibros
. 2024 Mar;
23(4):725-733.
PMID: 38429150
The COVID-19 pandemic necessitated a rapid shift in clinical research to perform virtual visits and remote endpoint assessments, providing a key opportunity to optimize the use of remote endpoints for...
7.
Graham B, Harris J, Zemanick E, Wagner B
Microbe
. 2024 Jan;
1.
PMID: 38264413
Host response to airway infections can vary widely. Cystic fibrosis (CF) pulmonary exacerbations provide an opportunity to better understand the interplay between respiratory microbes and the host. This study aimed...
8.
Miller J, Liu C, Zemanick E, Woods J, Goss C, Taylor-Cousar J, et al.
J Cyst Fibros
. 2023 Nov;
23(6):1195-1198.
PMID: 37981480
Background: Olfactory dysfunction (OD) is prevalent in people with cystic fibrosis (PwCF) and can negatively impact quality-of-life (QOL). This study evaluated perceptions of OD, investigated how OD impacts QOL, and...
9.
Wagner B, Zemanick E, Sagel S, Robertson C, Stevens M, Mayer-Hamblett N, et al.
BMC Microbiol
. 2023 Oct;
23(1):312.
PMID: 37891457
Background: Tobramycin inhalation solution (TIS) and chronic azithromycin (AZ) have known clinical benefits for children with CF, likely due to antimicrobial and anti-inflammatory activity. The effects of chronic AZ in...
10.
Mayer-Hamblett N, Clancy J, Jain R, Donaldson S, Fajac I, Goss C, et al.
Lancet Respir Med
. 2023 Sep;
11(10):932-944.
PMID: 37699421
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally altered clinical trial strategies needed to...